AVTX vs CUBE · P/E 0.0, rev $441.0K vs P/E 25, rev $1.07B
Avalo Therapeutics Inc (AVTX) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the AVTX and CUBE stock pages for the full models.
Not investment advice.